76
Participants
Start Date
August 23, 2021
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2026
Tideglusib
Tideglusib dosing will be weight-adjusted at 400 mg, 600 mg, or 1000 mg dose levels, or weight banded fixed doses of 400 mg, 600 mg, 800 mg or 1000 mg, with each subject starting at a weight-adjusted 400 mg dose level for 2 weeks, then up titrating to a weight-adjusted 600 mg dose level for the next 2 weeks.
COMPLETED
New Zealand Clinical Research (NZCR), Auckland
RECRUITING
The Bright Alliance, Randwick
RECRUITING
University of Rochester - Medical Center, Rochester
RECRUITING
University of Pittsburgh Medical Center, Pittsburgh
COMPLETED
Virginia Commonwealth University-Department of Neurology - Muscular Dystrophy Translational Research Program, Richmond
WITHDRAWN
Children's Hospital of The King's Daughters, Norfolk
RECRUITING
University of Iowa Hospitals and Clinics, Iowa City
RECRUITING
Lurie's Children's Hospital, Chicago
RECRUITING
Arkansas Children's Hospital, Little Rock
RECRUITING
University of Utah Clinical Neurosciences Center, Salt Lake City
ENROLLING_BY_INVITATION
University of California, Los Angeles (UCLA), Los Angeles
ENROLLING_BY_INVITATION
Stanford University, Palo Alto
ENROLLING_BY_INVITATION
Children's Hospital London Health Sciences Centre (LHSC), London
RECRUITING
Children's Hospital of Eastern Ontario, Ottawa
Lead Sponsor
AMO Pharma Limited
INDUSTRY